ONCODNA Provides an Update About the Friendly Takeover Bid on INTEGRAGEN
13 Août 2020 - 5:45PM
Business Wire
Regulatory News:
OncoDNA SA has become the first shareholder of IntegraGen SA
(Paris:ALINT), holding 29.99% of the existing shares, as result of
purchases of shares on the Euronext Growth market.
These acquisitions of shares of IntegraGen follow the filing of
a draft friendly takeover bid on the shares of IntegraGen SA with
the French Autorité des Marchés Financiers (AMF) on July 9th
2020.
At the date of filing of the draft offer, OncoDNA did not own
any share of IntegraGen.
The acquisitions of shares representing 29.99% of the share
capital of IntegraGen have been made on the market at the offer
price of 2.20 EUR/share in accordance with applicable
regulations.
The public offer remains subject to the approval of the AMF and
clearance by the French Ministry of Economy under foreign
investment control in France, and is expected to be opened at the
end of the third quarter of 2020.
OncoDNA remains enthusiast about the transaction and waits for
the next steps of the process. This transaction would bring
together OncoDNA’s expertise in oncology precision medicine and
IntegraGen’s know-how in DNA sequencing services and bioinformatics
analyses. The combination of both companies would enable to offer a
complete solution that combines most advanced oncology laboratory
testing and software solutions which will benefit the treatment of
patients with advanced cancer.
About OncoDNA
OncoDNA is a private, oncology-focused healthcare technology
company that combines advanced, comprehensive testing of all
clinically relevant cancer biomarkers (DNA, RNA and protein
profiles) from both solid and liquid biopsies with a proprietary
cancer treatment knowledge database called OncoKDO™ which
continuously ‘learns’ from cutting-edge, validated, scientific and
medical advances. This one-stop-shop analysis and interpretation
service gives oncologists actionable results to enable the
selection of treatments tailored to the individual patient’s cancer
profile.
OncoDNA provides to laboratories in the world equipped with NGS
equipment an access to a state-of-the-art interpretation software
to improve their routine oncology-oriented analyses. The SaaS
software OncoKDM is a web-based tool that processes oncology raw
NGS and molecular biology data to turn them into clinical insights
such as treatment options or clinical trials.
OncoDNA also works in collaboration with the biopharma industry
to develop and deliver the treatments of tomorrow by assisting in
the design, enrolment and assessment of clinical trials as well as
increasing access to approved precision medicines. The company is
based in Gosselies, Belgium, and counts 55 employees in five
countries.
www.oncodna.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200813005606/en/
Pierre FLAMANT – CFO p.flamant@oncodna.com Tél : +32 (0)71 183
350
Integragen (EU:ALINT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Integragen (EU:ALINT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024